An observational study in Diabete Mellitus, Retina Vein Occlusion and Age Macular Degeneration, sponsored by Ataturk University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by Ataturk University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 246 studies in Diabetes Mellitus with a site in Turkey — 37 open to participants now, 44 under way, 1 of them phase 3. Diabetes Mellitus · Turkey.
Among the 246 studies in Diabetes Mellitus with a site in Turkey, this one is the 36th largest by planned enrollment of the 97 observational ones that give a count, is one of 22 that started in 2025, is one of 97 observational ones, reaches primary completion later than 24 of the 43 other live ones, and was the 230th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →37 of the 246 studies in Diabetes Mellitus with a site in Turkey are open now. Recruiting first, the newest first:
Aylin DEMİR · Sites in Turkey
Ages 35–65
Bilecik Seyh Edebali Universitesi · Sites in Turkey
Ages 18–65
Abant Izzet Baysal University · Sites in Turkey
Ages 65+ · Healthy volunteers
Kırıkkale University · Sites in Turkey
Ages 30–75 · Men only · Healthy volunteers
Ege University · Sites in Turkey
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
246 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 38 · Phase 4 15
First in 2002; this study’s year is marked. 22 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is below the median of 246 across 1,935 observational studies indexed under Diabetes Mellitus.
Median enrollment 90 across the 147 interventional studies, 120 across the 97 observational. Of the 192 that completed or were terminated, 45 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 246 have an industry lead sponsor. The 10 most frequent:
Ataturk University is the lead sponsor of 463 studies on the registry; 123 are open to participants now.
Ataturk University has 6 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
8 of the studies in Diabetes Mellitus with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07491185Ege UniversityEffect of Glycemic Control on Intraoperative NIRS and Postoperative Recovery in Diabetic Patients | 2026-11 |
| NCT07444697Kırıkkale University"Erectile Function After PCI in MI and Non-MI Patients" | 2026-11 |
| NCT07734428Istanbul Bilgi UniversityInflammation and Diabetes: Evaluating Antioxidant Levels | 2026-12-30 |
| NCT07329985Bilecik Seyh Edebali UniversitesiFEAR of HYPOGLYCEMIA in PATIENTS WITH DIABETES | 2027-01-15 |
| NCT07905274Bandırma Onyedi Eylül UniversitySarcopenia Risk in Obese T2DM Patients | 2027-03-20 |
Add all 8 to your calendar (.ics) → With an account.
Among the 246 studies in Diabetes Mellitus with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Bevacizumab, an anti-VEGF (vascular endothelial growth factor) agent used in the treatment of diabetic retinopathy and macular edema associated with retinal vein occlusion, is commonly administered in ophthalmology clinics through intravitreal injection. The systemic use of bevacizumab has been associated with serious conditions such as thromboembolism and bleeding. Although intravitreal bevacizumab is administered in smaller amounts and has limited systemic circulation, it requires repeated injections over a long period. These long-term intravitreal anti-VEGF therapies may lead to adverse outcomes, particularly thromboembolism, due to systemic inhibition of VEGF. However, limited information is available regarding the potential effects of this treatment on the systemic and cardiovascular systems. To evaluate this risk, the study aims to assess changes in the activities of paraoxonase 1 (PON1), acetylcholinesterase (AChE), and butyrylcholinesterase (BChE), which are closely associated with lipid metabolism, coronary artery disease, and atherosclerosis. These enzymes are known biomarkers of cardiovascular health and play significant roles in protection against oxidative stress and inflammation. For this purpose, a case-control study is planned. Serum BChE and PON1 activities, as well as triglyceride (TG)/high-density lipoprotein (HDL) and TG/glucose ratios, will be determined in patients receiving repeated intravitreal bevacizumab injections and in control groups, and cardiovascular disease risk will be assessed. This study may help us better understand the safety profile of this treatment by revealing the effects of bevacizumab on serum enzyme activities and cardiovascular risk factors. These findings could contribute to optimizing treatment strategies in clinical practice.
The patient group consists of individuals receiving repeated doses of intravitreal bevacizumab treatment for diabetic macular edema, retinal vein occlusion, and age-related macular degeneration-related macular edema, along with a control group (the control group will also be divided into two subgroups: individuals with diabetes but without macular edema or diabetic retinopathy, and completely healthy individuals).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
glaucoma
uveitis
retinal dystrophies
significant media opacity preventing adequate ocular evaluation
- Use of systemic medications or conditions known to affect cholinesterase activity markedly
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: blood test
Procedure: blood test
Procedure: blood test
Procedure: blood test
Serum samples will be collected from the patient group included in the study starting from at least the second dose of intravitreal bevacizumab treatment. Serum samples will be collected within one week after the last injection.
Serum butyrylcholinesterase (BChE) activity
Description: Measurement of serum butyrylcholinesterase (BChE) activity in participants who received at least 2 consecutive intravitreal bevacizumab injections. Serum samples will be collected after the most recent injection, and BChE activity will be compared among subgroups defined by the number of previous consecutive injections (early: 2-3 doses; mid: 4-6 doses; long: \>6 doses).
Time frame: Within 7 days after the most recent intravitreal bevacizumab injection
Serum acetylcholinesterase (AChE) activity
Measurement of serum acetylcholinesterase (AChE) activity in participants who received at least 2 consecutive intravitreal bevacizumab injections. Serum samples will be collected after the most recent injection, and AChE activity will be compared among subgroups defined by the number of previous consecutive injections (early: 2-3 doses; mid: 4-6 doses; long: \>6 doses).
Time frame: Within 7 days after the most recent intravitreal bevacizumab injection
Serum paraoxonase-1 (PON1) activity
Measurement of serum paraoxonase-1 (PON1) activity in participants who received at least 2 consecutive intravitreal bevacizumab injections. Serum samples will be collected after the most recent injection, and PON1 activity will be compared among subgroups defined by the number of previous consecutive injections (early: 2-3 doses; mid: 4-6 doses; long: \>6 doses).
Time frame: Within 7 days after the most recent intravitreal bevacizumab injection
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Jun 2026, 7 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.